Sentinel Lymph Nodes Biopsy in Cervical Cancer

NCT06169787 — Unknown, 70 participants, Far Eastern Memorial Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Sentinel Lymph Nodes Biopsy Versus Lymphadenectomy in Cervical Cancer

RegistryNCT06169787
StatusUnknown
Study typeObservational
Enrollment70 (Estimated)
SponsorFar Eastern Memorial Hospital (Other)
ConditionsSentinel Lymph Node
Interventionssentinel lymph node biopsy, comprehensive pelvic lymphadenectomy (Procedure)
Datesstart 2023-10-14, primary completion 2024-08-31 (estimated), completion 2024-09-30 (estimated), first posted 2023-12-14, last updated 2024-06-17
Locations1 site in Taiwan

Related Papers Related Patents Related Grants Related Experts
All trials for Sentinel Lymph Node All trials of sentinel lymph node biopsy All trials of comprehensive pelvic lymphadenectomy

-Summary

This study aims to compare sentinel lymph nodes biopsy versus comprehensive lymphadenectomy in patients with early stage cervical cancer who underwent radical hysterectomy.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Sentinel Lymph NodeProcedure: sentinel lymph node biopsySentinel lymph node biopsy in patients with early stage cervical cancer
LymphadenectomyProcedure: comprehensive pelvic lymphadenectomyComprehensive lymphadenectomy in patients with early stage cervical cancer
  • sentinel lymph node biopsy (Procedure): sentinel lymph node biopsy
  • comprehensive pelvic lymphadenectomy (Procedure): comprehensive pelvic lymphadenectomy

+Outcome measures

Primary outcomes

  • progression free survival [5 years]: progression free survival between these two groups

Secondary outcomes

  • overall survival [5 years]: overall survival between these two groups
  • Number of dissected lymph node [5 years]: Number of dissected lymph node between these two groups

Other outcomes

  • Complications [5 years]: Compication rates between the traditional and sentinel lymph node dissection groups

+Eligibility

Sex: Female, ages: 20 Years to any

Inclusion Criteria:

Women aged 20 and above with clinical FIGO stage I-IIA cervical cancer

Exclusion Criteria:

Women did not receive surgical treatment

+Locations (1)

FacilityCityCountryStatus
Department of Obstetrics and Gynecology, Far Eastern Memorial HospitalBanqiao District, New TaipeiTaiwan